Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Hepatocellular Carcinoma
NCT04472767Phase 2Recruiting
- Sponsor
- University of California, Irvine
- Start
- Aug 2020
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib in hepatocellular carcinoma (HCC), sponsored by University of California, Irvine. Started Aug 2020; status: recruiting.
02
Drugs
cabozantinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04472767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04472767.